Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

#RGBP NR2F6 - Nuclear Receptor Identified. Demonstrates Very Important Immune Cell Inhibitor  & Cancer Stem Cell Differentiator

|About: Regen Biopharma, Inc. (RGBP)

Summary

Focus on Small Molecoules

NR2F6

Immune Cell Inhibitor/Activator

Cancer Stem Cell Differentiator

Unleash Cancer-Killing Potential

www.regenbiopharmainc.com

#RGBP NR2F6 - Nuclear Receptor Identified. Demonstrates Very Important Immune Cell Inhibitor (an immune checkpoint) & Cancer Stem Cell Differentiator (This effort is to unleash the cancer-killing potential of a patient's own immune system)

Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6

https://s.yimg.com/bt/api/res/1.2/rixB6Tpfff9ttf8dOghHpg--/YXBwaWQ9eW5ld3M7c209MTt3PTg0O2g9ODQ7aWw9cGxhbmU-/http:/l.yimg.com/os/creatr-images/GLB/2017-04-05/a35fec90-1a09-11e7-a48d-afa853618fa3_64x64.jpg

PR NewswireOctober 3, 2017

Comment


SAN DIEGO, October 3, 2017 /PRNewswire/ --

Regen BioPharma Inc. (RGBP) and (RGBPP) scientists have used a standard biochemical assay to determine if some of its small molecules that have been shown to activate NR2F6 in cells, physically interact with NR2F6 in vitro. The Company reports that the experiments indicate that some of Regen's proprietary small molecules bind to, and alter the structure of NR2F6.

Regen BioPharma, Inc. Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6

RGBP Issues End Of Fiscal Year Shareholder Letter - News On Cancer Testing

The Marketplace: 

Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning.  Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (Gilead Sciences to Acquire Kite Pharma for $11.9 Billion | Gilead).  

A Look Back at our Success: 

The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity.  Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.  

Plans for the Immediate Future: 

We continue to have discussions with multiple big pharma companies.To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.

Read More: Regen BioPharma Issues End of Fiscal Year Shareholder Letter

$RGBP - Major Breakthrough - Discovers Compound 10X More Effective - Cancer-Killing Potential Using Patient's Own Immune System

(OTCQB:) Regen BioPharma, Inc. Sees New-Additional Positive Results for NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases

Regen BioPharma, Inc. Announces the Company Canceled 31.5 Million Shares

Previous Items of Significance:

HemaXellerate’s approval and clearance by the FDA to commence Human Trials with the New Drug. That resulted in two things. One RGBP transitioned from a R&D company, morphing into a Clinical Trials Company, a major step in the progress of the company and credibility. Second RGBP attracted their first viable partner as the (NIH) agency NCATS agreed to collaborate with clinical trials using HemaXellerate for a treatment of the rare blood disease/disorder aPlastic Anemia.

New Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company – Weill Cornell Medical College (Cornell University) - Chem Div

HemaXellerate II was discovered to be effective in treating an additional market much more vast than aPlastic Anemia. It is in the early stage of development to treat Bone Marrow Suppression, a common disorder due to Chemotherapy. This finding occurred at/with another new partner The Pan Am Cancer Research and Treatment Center where ongoing Trials are being conducted.

Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product

dCell Vax (Treatment for Breast Cancer) seems to be at last news in the final comments with the FDA to gain approval to commence Human Trials with Breast Cancer Patients.

The NIH (NCATS) also is collaborating with Regen and working together to screen small molecule compounds that activate or inhibit orphan nuclear receptor, NR2F6 (Research Project), cell lines will be provided by Regen. Regen also has a partnership with Eli Lily working together with NR2F6.

For all the news-Details on other treatments HemaXellerate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, uCell Vax, Car-T Cell for various Cancers, Autoimmune, Rare Blood Disorders/Diseases, Leukemia, etc. Open the link below.

We believe Regen BioPharma is a Long Play, with a great upside with all the items in its Pipeline. Very possibly a Buy Out Target.

RGBP also has Short Term Gain Potential that has been proven time and again since we began following them. Increases-Bounces in Share Pricing ranging from 30%-400% and more at various intervals.

Research and Due Diligence Visit:  sec.gov   otcmarkets.com   yahoofinance.com 

If you have any questions concerning (OTCQB:) or have a need for more information, please feel free to contact me. 

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

robkreh@gmail.com 

(OTCQB:RGBP) Disclaimer:

You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker()/Broker Dealer() with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.